News
Public · Published
Prestige Consumer Healthcare 3Q 2026: Revenue $336.31M, EPS $0.53 — 10-Q Summary
Prestige Consumer Healthcare reported second-quarter revenue of $336.31 million, up 22.7% year over year, while net income fell 40.1% and diluted earnings per share declined 38.4% to $0.53. Revenue growth reflected acquisitions, while lower gross margins and higher costs weighed on earnings.
Published:
Updated:
What happened
Prestige Consumer Healthcare reported second-quarter revenue of $336.31 million, up 22.7% year over year, while net income fell 40.1% and diluted earnings per share declined 38.4% to $0.53. Revenue growth reflected acquisitions, while lower gross margins and higher costs weighed on earnings.
Confirmed
Global impact / market context
The results show that acquired sales growth did not translate into higher earnings: lower gross profit per dollar of sales, increased marketing and interest costs, and a higher tax rate reduced profits. Continued supply problems could also limit product availability and constrain revenue if not resolved.
Analyst inference
The article describes acquisition-led growth alongside weaker profitability and operational strain. Investors assessing the business may weigh whether added sales can cover acquisition-related costs and restore profit per sale, while supply remediation and facility improvements could add costs before they support steadier production.
Analyst inference
What to watch
- Watch whether revenue growth continues in later results and whether the company reports gains beyond those attributed to the OTC Wellness Business and other acquisitions. Analyst inference
- Track gross margin, meaning gross profit as a share of revenue, and whether it improves from 51.3% as facility improvement costs and acquired-inventory charges change. Analyst inference
- Follow updates on sterile eye-care shortages and quality-system work; lasting supply disruption could restrict product availability, weigh on sales, and require further remediation spending. Analyst inference
Evidence
- Original source link unavailable